PureTech Health PLC Net Income
| PRTC Stock | USD 16.64 -0.22 -1.30% |
Momentum
Impartial
Oversold | Overbought |
As of the 16th of March 2026, PureTech Health is marked at 16.64 per share. Recent trend indicators show Semi Deviation of 2.09, coefficient of variation of 11850.18, and Risk Adjusted Performance of 0.0136. Trend analytics rely on normalized volatility and volume metrics. Trend metrics are reviewed within historical sector ranges.
Forward estimates place Total Revenue near 5.38 Million, implying a easing bias. PureTech Health entered the current period with Total Revenue of 4.35 Million on the books. Recent filings indicate that Pretax Profit Margin continues rebounding. Year-ago financials show PureTech Health with Pretax Profit Margin of 4.43. Per market data dated March 16, 2026, Net Profit Margin is projected to grow to 13.38, whereas our analysis places Operating Profit Margin near -34.04 following downward revisions. PureTech Health Total Revenue | 5.38 Million |
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 14.7014 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 31.9 M | 33.5 M | |
| Net Income From Continuing Ops | 31.9 M | 33.5 M | |
| Net Loss | -69.6 M | -66.2 M | |
| Net Income Per Share | 1.79 | 1.88 | |
| Net Income Per E B T | 2.03 | 2.13 |
PureTech | Net Income | Build AI portfolio with PureTech Stock |
Analyzing PureTech Health's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing PureTech Health's current valuation and future prospects.
Latest PureTech Health's Net Income Growth Pattern
Below is the plot of the Net Income of PureTech Health PLC over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in PureTech Health PLC financial statement analysis. It represents the amount of money remaining after all of PureTech Health PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is PureTech Health's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PureTech Health's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 27.78 M | 10 Years Trend |
|
Net Income |
| Timeline |
PureTech Net Income Regression Statistics
| Arithmetic Mean | 14,711,813 | |
| Coefficient Of Variation | 767.47 | |
| Mean Deviation | 65,660,442 | |
| Median | -11,054,000 | |
| Standard Deviation | 112,908,384 | |
| Sample Variance | 12748.3T | |
| Range | 486.8M | |
| R-Value | 0.17 | |
| Mean Square Error | 13182.3T | |
| R-Squared | 0.03 | |
| Significance | 0.50 | |
| Slope | 3,910,226 | |
| Total Sum of Squares | 203972.9T |
PureTech Net Income History
Other Fundumenentals of PureTech Health PLC
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
PureTech Health Net Income component correlations
PureTech Net Income Driver Correlations
Sound financial modeling for PureTech Health requires a clear understanding of how PureTech Health's accounts, including Net Income, are correlated. Because PureTech Health's income statement, balance sheet, and cash flow items are all interconnected, a correlation-based approach to analysis is more effective than examining each statement independently.
Click cells to compare fundamentals
Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
Investors evaluate PureTech Health PLC using market value and book value, each describing different facets of the business. PureTech Health's market capitalization is 402.37 M. A P/B ratio of 1.07 indicates the market values PureTech Health above its accounting book value. Enterprise value stands at 90.65 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that PureTech Health's intrinsic value and market price are different measures derived from different inputs. For PureTech Health, key inputs include a P/B ratio of 1.07, a profit margin of 7.93%, ROE of 9.44%, and revenue of 4.83 M. The quoted PureTech Health price is the exchange level where supply meets demand.
What if' Analysis
Running a what-if backtest on PureTech Health PLC gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. The stronger interpretation comes from comparing realized return, risk, and path dependency instead of focusing only on the best historical outcome.
| 12/16/2025 |
| 03/16/2026 |
An initial 0.00 allocation to PureTech Health on December 16, 2025 held through today would produce 0.00 in overall gains. That corresponds to a 0.0% cumulative return in PureTech Health on balance over 90 days. PureTech Health is often compared with Autolus Therapeutics, Neurogene, Solid Biosciences, QuantumSi, Lineage Cell, Benitec Biopharma, and ADC Therapeutics based on sector and business overlap. Peer context can support comparative analysis. PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inf... More
PureTech Health Upside and Downside Indicators Overview
These indicators describe how PureTech Health momentum evolves across recent price ranges. They provide a structured view of short-term momentum and range behavior.
| Downside Deviation | 2.67 | |||
| Information Ratio | 0.0221 | |||
| Maximum Drawdown | 15.3 | |||
| Value At Risk | -3.57 | |||
| Potential Upside | 4.35 |
Volatility and Risk Indicators for PureTech Health Summary
These indicators track PureTech Health's volatility and return range dynamics. The metrics rely on historical prices to describe variability over time.| Risk Adjusted Performance | 0.0136 | |||
| Jensen Alpha | 0.0217 | |||
| Total Risk Alpha | 0.155 | |||
| Sortino Ratio | 0.0211 | |||
| Treynor Ratio | 0.0503 |
The degree to which PureTech Health's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0136 | |||
| Market Risk Adjusted Performance | 0.0603 | |||
| Mean Deviation | 1.73 | |||
| Semi Deviation | 2.09 | |||
| Downside Deviation | 2.67 | |||
| Coefficient Of Variation | 11850.18 | |||
| Standard Deviation | 2.55 | |||
| Variance | 6.48 | |||
| Information Ratio | 0.0221 | |||
| Jensen Alpha | 0.0217 | |||
| Total Risk Alpha | 0.155 | |||
| Sortino Ratio | 0.0211 | |||
| Treynor Ratio | 0.0503 | |||
| Maximum Drawdown | 15.3 | |||
| Value At Risk | -3.57 | |||
| Potential Upside | 4.35 | |||
| Downside Variance | 7.14 | |||
| Semi Variance | 4.37 | |||
| Expected Short fall | -2.21 | |||
| Skewness | 0.9257 | |||
| Kurtosis | 3.28 |
PureTech Health PLC Backtested Returns
PureTech Health registers a low volatility profile across the specified investment window. It exhibits a Sharpe Ratio of close to zero, capturing return dispersion relative to standard deviation. Algorithmic screening detected thirty volatility-sensitive metrics. Please evaluate metrics such as Semi Deviation of 2.09, coefficient of variation of 11850.18, and risk-adjusted performance of 0.0136 to validate implied downside exposure. The company owns a Beta (Systematic Risk) of 0.23, which means relatively modest fluctuations relative to the market. As returns on the market increase, PureTech Health's returns are expected to increase less than the market. However, during a bear market, the loss from holding PureTech Health is expected to be smaller as well. PureTech Health PLC right now owns a risk of 2.64%. Please confirm PureTech Health expected short fall, and the relationship between the value at risk and daily balance of power.
Auto-correlation | -0.67 |
Very good reverse predictability
Comparing PureTech Health's price behavior from 16th of December 2025 to 30th of January 2026 with the period from 30th of January 2026 to 16th of March 2026 produces very good reverse predictability. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of PureTech Health PLC may be projected. The coefficient of -0.67 links around 67.0% of PureTech Health's present price action to its own historical movements. Given that PureTech Health PLC has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.67 | |
| Spearman Rank Test | -0.69 | |
| Residual Average | 0.0 | |
| Price Variance | 0.42 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
PureTech Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income | 161.76 Million |
Based on the recorded statements, PureTech Health PLC reported net income of 27.78 M. This is 91.86% lower than that of the Biotechnology sector and 60.34% lower than that of the Health Care industry. The net income for all United States stocks is 95.13% higher than that of the company.
PureTech Net Income Peer Comparison
Stock peer comparison using Net Income is a reliable method for evaluating PureTech Health against comparable stocks. Investors use PureTech Health's Net Income relative to peers to identify whether the stock is attractively or expensively valued.PureTech Health is currently under evaluation for net income relative to top peers.
PureTech Health Current Valuation Drivers
The key financial drivers used in PureTech Health valuation scoring are derived from an analysis of PureTech Health's financial statements. These drivers evaluate PureTech Health's ability to generate profit from its revenue while managing operational costs and equity.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.6B | 1.1B | 892.4M | 778.6M | 700.8M | 643.9M | |
| Enterprise Value | 1.3B | 647.4M | 789.4M | 612.9M | 551.6M | 528.1M |
PureTech Health ESG Sustainability
Companies with high ESG scores, including PureTech Health, often attract premium market valuations. Although PureTech Health's ESG disclosures are largely voluntary, they offer investors a meaningful view of the company's governance practices and long-term commitments.Environmental | Governance | Social |
PureTech Health Institutional Holders
The institutional investor base for PureTech Health comprises large financial entities such as pension funds, endowments, and investment managers that hold PureTech Health's shares. Because of the size of their positions, institutional investors can meaningfully influence PureTech Health's.| Shares | Lansdowne Partners Limited Partnership | 2025-09-30 | 14.1 M | Pentwater Capital Management Lp | 2025-12-31 | 70 K | Millennium Management Llc | 2025-12-31 | 15.4 K | Diadema Partners Lp | 2025-09-30 | 7.3 K | Persistent Asset Partners Limited | 2025-12-31 | 1.8 K | Ubs Group Ag | 2025-09-30 | 20.0 | Portolan Capital Management, Llc | 2025-09-30 | 0.0 | Atlantic Union Bankshares Corp | 2025-09-30 | 0.0 | Birch Hill Investment Advisors Llc | 2025-09-30 | 0.0 | Sbi Securities Co Ltd | 2025-12-31 | 0.0 |
PureTech Fundamentals
| Return On Equity | 0.0944 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | 7.93 % | ||||
| Operating Margin | -25.90 % | ||||
| Current Valuation | 90.65 M | ||||
| Shares Outstanding | 24.18 M | ||||
| Shares Owned By Institutions | 0.39 % | ||||
| Number Of Shares Shorted | 4.71 K | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 62.96 X | ||||
| Revenue | 4.83 M | ||||
| Gross Profit | -48.81 M | ||||
| EBITDA | 37.38 M | ||||
| Net Income | 27.78 M | ||||
| Cash And Equivalents | 368.03 M | ||||
| Cash Per Share | 12.84 X | ||||
| Total Debt | 22.36 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 2.54 X | ||||
| Book Value Per Share | 1.56 X | ||||
| Cash Flow From Operations | -134.37 M | ||||
| Short Ratio | 2.15 X | ||||
| Earnings Per Share | 1.70 X | ||||
| Target Price | 46.0 | ||||
| Number Of Employees | 56 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 402.37 M | ||||
| Total Asset | 602.63 M | ||||
| Retained Earnings | 32.49 M | ||||
| Working Capital | 344.87 M | ||||
| Net Asset | 602.63 M |
Financial Metrics, Fundamentals & Methodology
PureTech Health reports annual revenue of 4.83 M, a profit margin of 7.93%, ROE of 9.44%, debt-to-equity of 0.08. A closer look at PureTech Health highlights capital structure dynamics and profitability sustainability. Cash reserves enhance macroeconomic adaptability. For this reporting period, PureTech Health reflects revenue of 4.83 M, positive EPS of 1.7, negative operating margin of 25.9%.
Unless otherwise specified, data for PureTech Health PLC is compiled from periodic company reporting and market reference feeds and standardized for comparability. Where analyst coverage exists, consensus estimates are factored in. Updates may occur throughout the day. Financial statement fields are presented under issuer-reported GAAP or IFRS accounting conventions.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for PureTech Stock Analysis
A structured review of PureTech Health PLC often starts with core financial statements and trend context. Ratio analysis helps investors evaluate PureTech Health PLC Stock operating efficiency and financial trajectory. Highlighted below are reports that provide context for PureTech Health PLC Stock: Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
Investors evaluate PureTech Health PLC using market value and book value, each describing different facets of the business. PureTech Health's market capitalization is 402.37 M. A P/B ratio of 1.07 indicates the market values PureTech Health above its accounting book value. Enterprise value stands at 90.65 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that PureTech Health's intrinsic value and market price are different measures derived from different inputs. For PureTech Health, key inputs include a P/B ratio of 1.07, a profit margin of 7.93%, ROE of 9.44%, and revenue of 4.83 M. The quoted PureTech Health price is the exchange level where supply meets demand.